These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 12778627

  • 1. [Pleiotropic effect of the micronized fenofibrate: the reduction of plasma chlamydia pneumoniae antibody levels in patients with coronary artery disease].
    Márk L, Márki-Zay J, Orosz I, Kondacs A, Erdei F, Katona A.
    Orv Hetil; 2003 Apr 20; 144(16):765-8. PubMed ID: 12778627
    [Abstract] [Full Text] [Related]

  • 2. Chlamydia pneumoniae infection and accelerated development of coronary artery disease in patients with chronic renal failure.
    Song H, Tasaki H, Yashiro A, Okazaki M, Ioka T, Taniguchi H, Nakashima Y.
    Clin Nephrol; 2001 Nov 20; 56(5):346-52. PubMed ID: 11758004
    [Abstract] [Full Text] [Related]

  • 3. Relationship between dyslipidemia, C-reactive protein and serological evidence of Chlamydia pneumoniae in Turkish patients with coronary artery diseases.
    Turkoglu C, Sonmez E, Aydinli A.
    New Microbiol; 2004 Jul 20; 27(3):229-34. PubMed ID: 15460525
    [Abstract] [Full Text] [Related]

  • 4. Role of Chlamydia pneumoniae, helicobacter pylori and cytomegalovirus in coronary artery disease.
    Al-Ghamdi A, Jiman-Fatani AA, El-Banna H.
    Pak J Pharm Sci; 2011 Apr 20; 24(2):95-101. PubMed ID: 21454155
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Effect of micronized fenofibrate (lipantyl-200M) on synthesis of cholesterol in peripheral blood lymphocytes of patients with ischemic heart disease and hyperlipidemia].
    Ivanova TN, Poliakova ED, Olfer'ev AM, Perova NV.
    Biull Eksp Biol Med; 1998 May 20; 125(5):569-73. PubMed ID: 9644562
    [No Abstract] [Full Text] [Related]

  • 7. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
    Zhu J, Ye P.
    Chin Med J (Engl); 2003 Jun 20; 116(6):840-3. PubMed ID: 12877791
    [Abstract] [Full Text] [Related]

  • 8. Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
    Yeganeh B, Moshtaghi-Kashanian GR, Declercq V, Moghadasian MH.
    J Nutr Biochem; 2005 Apr 20; 16(4):222-8. PubMed ID: 15808326
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
    Maciejewski S, Hilleman D.
    Pharmacotherapy; 2008 May 20; 28(5):570-5. PubMed ID: 18447655
    [Abstract] [Full Text] [Related]

  • 10. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 20; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Incidence of Chlamydia pneumoniae infection in patients with coronary artery disease subjected to angioplasty or bypass surgery.
    Pieniazek P, Karczewska E, Stepień E, Tracz W, Konturek SJ.
    Med Sci Monit; 2001 Oct 20; 7(5):995-1001. PubMed ID: 11535948
    [Abstract] [Full Text] [Related]

  • 13. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun 20; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 14. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia.
    de la Serna G, Cadarso C.
    Clin Pharmacol Ther; 1999 Aug 20; 66(2):166-72. PubMed ID: 10460070
    [Abstract] [Full Text] [Related]

  • 15. [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].
    Okopień B, Cwalina Ł, Haberka M, Kowalski J, Zieliński M, Szwed Z, Kalina Z, Herman ZS.
    Pol Merkur Lekarski; 2002 Dec 20; 13(78):465-9. PubMed ID: 12666442
    [Abstract] [Full Text] [Related]

  • 16. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
    Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC.
    Ann Clin Lab Sci; 2007 Dec 20; 37(2):158-66. PubMed ID: 17522372
    [Abstract] [Full Text] [Related]

  • 17. Interaction between Chlamydia pneumoniae seropositivity, inflammation and risk factors for atherosclerosis in patients with severe coronary stenosis.
    Yavuz MT, Yavuz O, Yazici M, Guler S, Ozhan H, Albayrak S, Coskun A.
    Scand J Clin Lab Invest; 2006 Dec 20; 66(6):523-34. PubMed ID: 17000560
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.